

Calithera Biosciences, Inc.  
 Form 3  
 October 01, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Å Sjogren Eric  
 (Last) (First) (Middle)

2. Date of Event Requiring Statement  
 (Month/Day/Year)  
 10/01/2014

3. Issuer Name and Ticker or Trading Symbol  
 Calithera Biosciences, Inc. [CALA]

4. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

5. If Amendment, Date Original Filed(Month/Day/Year)

C/O CALITHERA  
 BIOSCIENCES, INC., Å 343  
 OYSTER POINT BLVD. #200  
 (Street)

Director  10% Owner  
 Officer  Other  
 (give title below) (specify below)  
 SR. VP, DRUG DISCOVERY

SOUTH SAN FRANCISCO, Å CA Å 94080  
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK	11,631	D	Å

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

Edgar Filing: Calithera Biosciences, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
STOCK OPTION (RIGHT TO BUY)	Â (1)	09/29/2020	COMMON STOCK	1,833	\$ 9.6	D	Â
STOCK OPTION (RIGHT TO BUY)	Â (2)	12/13/2021	COMMON STOCK	8,209	\$ 0.48	D	Â
STOCK OPTION (RIGHT TO BUY)	Â (3)	06/12/2022	COMMON STOCK	8,601	\$ 0.48	D	Â
STOCK OPTION (RIGHT TO BUY)	Â (4)	05/22/2023	COMMON STOCK	21,739	\$ 0.96	D	Â
STOCK OPTION (RIGHT TO BUY)	Â (5)	12/16/2023	COMMON STOCK	37,991	\$ 2.64	D	Â
STOCK OPTION (RIGHT TO BUY)	Â (6)	09/08/2024	COMMON STOCK	18,740	\$ 7.2	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sjogren Eric C/O CALITHERA BIOSCIENCES, INC. 343 OYSTER POINT BLVD. #200 SOUTH SAN FRANCISCO, CA 94080	Â	Â	Â SR. VP, DRUG DISCOVERY	Â

## Signatures

/s/ Eric Sjogren                      10/01/2014  
 \*\*Signature of                      Date  
 Reporting Person

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/48 of the Option vests in equal monthly installments one month from 06/01/2010. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
  - (2) 1/48 of the Option vests in equal monthly installments one month from 11/07/2011. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
  - (3) 1/48 of the Option vests in equal monthly installments one month from 03/27/2012. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
  - (4) 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
  - (5) 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
  - (6) 1/48 of the Option vests in equal monthly installments one month from 09/09/2014. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

## Edgar Filing: Calithera Biosciences, Inc. - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.